{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:17Z","timestamp":1793230457775,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Women\u2019s Mental Health during the Reproductive lifespan - WoMHeR"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidence suggests beneficial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October\n \n \n $$30{th}$$<\/jats:tex-math>\n \n \n 30<\/mml:mn>\n \n th<\/mml:mi>\n <\/mml:mrow>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n , 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random-effects empirical Bayes model.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Our search retrieved 259 studies, eight of which met\u00a0the inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of\n \n \n $$- \\;8.94$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 8.94<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n points (CI [\n \n \n $$- \\;10.04, - \\;7.84$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 10.04<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 7.84<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} < 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n <<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) in the BDI scale, of\n \n \n $$- \\;5.90$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 5.90<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n points (CI [\n \n \n $$- \\;9.92, - \\;1.88$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 9.92<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 1.88<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} < 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n <<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) in the BDI-II scale and of\n \n \n $$- \\;6.19$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 6.19<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n points (CI [\n \n \n $$- \\;9.52, - \\;2.86$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 9.52<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 2.86<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} < 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n <<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of\n \n \n $$- \\;4.10$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 4.10<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n (CI [\n \n \n $$- \\;7.31, - \\;0.89$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 7.31<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 0.89<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} = 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n =<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) points in the HIT6 scale,\n \n \n $$- \\;32.05$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 32.05<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n (CI [\n \n \n $$- \\;55.96, - \\;8.14$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 55.96<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 8.14<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} = 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n =<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) in the MIDAS scale,\n \n \n $$- \\;1.7$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 1.7<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n (CI [\n \n \n $$- \\;3.27, - \\;0.13$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 3.27<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 0.13<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} = 0.03$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n =<\/mml:mo>\n 0.03<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) points in the VAS scale and of\n \n \n $$- \\;6.27$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 6.27<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n (CI [\n \n \n $$- \\;8.48, - \\;4.07$$<\/jats:tex-math>\n \n \n -<\/mml:mo>\n \n 8.48<\/mml:mn>\n ,<\/mml:mo>\n -<\/mml:mo>\n \n 4.07<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ],\n \n \n $$\\hbox {p} < 0.01$$<\/jats:tex-math>\n \n \n p<\/mml:mtext>\n <<\/mml:mo>\n 0.01<\/mml:mn>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Treatment with onabotulinumtoxinA leads to a significant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with beneficial effects specifically seen for certain migraine features.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12967-021-02801-w","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T06:03:18Z","timestamp":1617170598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-0185","authenticated-orcid":false,"given":"Oreste","family":"Affatato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago C.","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pisanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Babasieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif I.","family":"Aydinlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Chubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mwinyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"Suppl 2","key":"2801_CR1","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1007\/s10072-007-0771-7","volume":"28","author":"F Frediani","year":"2007","unstructured":"Frediani F, Villani V. Migraine and depression. Neurol Sci. 2007;28(Suppl 2):S161\u20135. https:\/\/doi.org\/10.1007\/s10072-007-0771-7.","journal-title":"Neurol Sci"},{"issue":"2","key":"2801_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10194-010-0282-4","volume":"12","author":"F Antonaci","year":"2011","unstructured":"Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011;12(2):115\u201325. https:\/\/doi.org\/10.1007\/s10194-010-0282-4 (Epub 2011 Jan 6).","journal-title":"J Headache Pain."},{"issue":"8","key":"2801_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1212\/01.wnl.0000058907.41080.54","volume":"60","author":"N Breslau","year":"2003","unstructured":"Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60(8):1308\u201312. https:\/\/doi.org\/10.1212\/01.wnl.0000058907.41080.54.","journal-title":"Neurology."},{"issue":"23","key":"2801_CR4","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1212\/WNL.0b013e318295d69e","volume":"80","author":"LS Gudmundsson","year":"2013","unstructured":"Gudmundsson LS, Scher AI, Sigurdsson S, et al. Migraine, depression, and brain volume: the AGES-Reykjavik Study. Neurology. 2013;80(23):2138\u201344. https:\/\/doi.org\/10.1212\/WNL.0b013e318295d69e.","journal-title":"Neurology."},{"issue":"2","key":"2801_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/PRA.0000000000000136","volume":"22","author":"AK Parsaik","year":"2016","unstructured":"Parsaik AK, Mascarenhas SS, Hashmi A, et al. Role of botulinum toxin in depression. J Psychiatr Pract. 2016;22(2):99\u2013110. https:\/\/doi.org\/10.1097\/PRA.0000000000000136.","journal-title":"J Psychiatr Pract."},{"issue":"1","key":"2801_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/PRS.0000000000005111","volume":"143","author":"E Bruloy","year":"2019","unstructured":"Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019;143(1):239\u201350. https:\/\/doi.org\/10.1097\/PRS.0000000000005111.","journal-title":"Plast Reconstr Surg."},{"issue":"1","key":"2801_CR7","doi-asserted-by":"publisher","first-page":"14720","DOI":"10.1038\/s41598-018-33119-1","volume":"8","author":"MB Lewis","year":"2018","unstructured":"Lewis MB. The interactions between botulinum-toxin-based facial treatments and embodied emotions. Sci Rep. 2018;8(1):14720. https:\/\/doi.org\/10.1038\/s41598-018-33119-1.","journal-title":"Sci Rep."},{"issue":"2","key":"2801_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cps.2020.01.003","volume":"47","author":"D Olla","year":"2020","unstructured":"Olla D, Sawyer J, Sommer N, Moore JB 4th. Migraine Treatment. Clin Plast Surg. 2020;47(2):295\u2013303. https:\/\/doi.org\/10.1016\/j.cps.2020.01.003.","journal-title":"Clin Plast Surg."},{"issue":"1","key":"2801_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92. https:\/\/doi.org\/10.1186\/s10194-019-1038-4.","journal-title":"J Headache Pain."},{"issue":"2","key":"2801_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","volume":"15","author":"T Sprenger","year":"2018","unstructured":"Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):313\u201323. https:\/\/doi.org\/10.1007\/s13311-018-0621-8.","journal-title":"Neurotherapeutics."},{"key":"2801_CR11","doi-asserted-by":"publisher","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","volume":"9","author":"CP Herd","year":"2019","unstructured":"Herd CP, Tomlinson CL, Rick C, et al. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019;9:e027953. https:\/\/doi.org\/10.1136\/bmjopen-2018-027953.","journal-title":"BMJ Open"},{"issue":"7","key":"2801_CR12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLOS Medicine."},{"key":"2801_CR13","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"2801_CR14","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406\u201318. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01766.x.","journal-title":"Headache."},{"issue":"14","key":"2801_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"19","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;19(14):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol."},{"key":"2801_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12874-018-0618-3","volume":"19","author":"SE Seide","year":"2019","unstructured":"Seide SE, R\u00f6ver C, Friede T. Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. BMC Med Res Methodol. 2019;19:16. https:\/\/doi.org\/10.1186\/s12874-018-0618-3.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"2801_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-0033-1356093","volume":"82","author":"AE Hawlik","year":"2014","unstructured":"Hawlik AE, Freudenmann RW, Pinkhardt EH, Sch\u00f6nfeldt-Lecuona CJ, Gahr M. Botulinumtoxin bei der Behandlung depressiver St\u00f6rungen [Botulinum toxin for the treatment of major depressive disorder]. Fortschr Neurol Psychiatr. 2014;82(2):93\u20139. https:\/\/doi.org\/10.1055\/s-0033-1356093 (Epub 2014 Feb 11).","journal-title":"Fortschr Neurol Psychiatr."},{"issue":"1","key":"2801_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-017-0723-4","volume":"18","author":"EI Aydinlar","year":"2017","unstructured":"Aydinlar EI, Dikmen PY, Kosak S, Kocaman AS. OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. J Headache Pain. 2017;18(1):23. https:\/\/doi.org\/10.1186\/s10194-017-0723-4 (Epub 2017 Feb 17).","journal-title":"J Headache Pain."},{"issue":"7","key":"2801_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10072-016-2568-z","volume":"37","author":"M Russo","year":"2016","unstructured":"Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P. The use of onabotulinum toxin A (Botox(\u00ae)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurol Sci. 2016;37(7):1127\u201331. https:\/\/doi.org\/10.1007\/s10072-016-2568-z (Epub 2016 Apr 5).","journal-title":"Neurol Sci."},{"issue":"9","key":"2801_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/head.12657","volume":"55","author":"K Maasumi","year":"2015","unstructured":"Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Headache. 2015;55(9):1218\u201324. https:\/\/doi.org\/10.1111\/head.12657 (Epub 2015 Sep 18).","journal-title":"Headache."},{"issue":"8","key":"2801_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/IJGM.S70456","volume":"18","author":"GP Boudreau","year":"2015","unstructured":"Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;18(8):79\u201386. https:\/\/doi.org\/10.2147\/IJGM.S70456.","journal-title":"Int J Gen Med."},{"issue":"5","key":"2801_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","volume":"123","author":"K Kollewe","year":"2016","unstructured":"Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm. 2016;123(5):533\u201340. https:\/\/doi.org\/10.1007\/s00702-016-1539-0 (Epub 2016 Mar 31).","journal-title":"J Neural Transm."},{"issue":"11","key":"2801_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10072-016-2665-z","volume":"37","author":"BE Demiryurek","year":"2016","unstructured":"Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG, Gungen BD. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci. 2016;37(11):1779\u201384. https:\/\/doi.org\/10.1007\/s10072-016-2665-z (Epub 2016 Jul 14).","journal-title":"Neurol Sci."},{"key":"2801_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-016-0634-9","volume":"17","author":"S Guerzoni","year":"2015","unstructured":"Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain. 2015;17:48. https:\/\/doi.org\/10.1186\/s10194-016-0634-9 (Epub 2016 May 4).","journal-title":"J Headache Pain."},{"issue":"3","key":"2801_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","volume":"90","author":"AM Blumenfeld","year":"2019","unstructured":"Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, Silberstein SD. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry. 2019;90(3):353\u201360. https:\/\/doi.org\/10.1136\/jnnp-2018-319290 (Epub 2019 Jan 10).","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"2801_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/09540261.2017.1326882","volume":"29","author":"F Amoozegar","year":"2017","unstructured":"Amoozegar F. Depression comorbidity in migraine. Int Rev Psychiatry. 2017;29(5):504\u201315. https:\/\/doi.org\/10.1080\/09540261.2017.1326882 (Epub 2017 Jul 6).","journal-title":"Int Rev Psychiatry."},{"issue":"7","key":"2801_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/dsu.12175","volume":"39","author":"D Hexsel","year":"2013","unstructured":"Hexsel D, Brum C, Siega C, Schilling-Souza J, Dal\u2019Forno T, Heckmann M, Rodrigues TC. Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg. 2013;39(7):1088\u201396. https:\/\/doi.org\/10.1111\/dsu.12175 (Epub 2013 Mar 6).","journal-title":"Dermatol Surg."},{"issue":"5","key":"2801_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1524-4725.2006.32136.x","volume":"32","author":"E Finzi","year":"2006","unstructured":"Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32(5):645\u20139. https:\/\/doi.org\/10.1111\/j.1524-4725.2006.32136.x (Discussion 649-50).","journal-title":"Dermatol Surg."},{"issue":"5","key":"2801_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer MA, de Boer C, Kalak N, Beck J, G\u00f6tz T, Schmidt T, Hodzic M, Bayer U, Kollmann T, Kollewe K, S\u00f6nmez D, Duntsch K, Haug MD, Schedlowski M, Hatzinger M, Dressler D, Brand S, Holsboer-Trachsler E, Kruger TH. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574\u201381. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.01.027 (Epub 2012 Feb 24).","journal-title":"J Psychiatr Res."},{"issue":"7","key":"2801_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676 (Epub 2010 Mar 17).","journal-title":"Cephalalgia."},{"issue":"7","key":"2801_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314. https:\/\/doi.org\/10.1177\/0333102410364677 (Epub 2010 Mar 17).","journal-title":"Cephalalgia."},{"issue":"2","key":"2801_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1526-4610.2007.00963.x","volume":"48","author":"FG Freitag","year":"2008","unstructured":"Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008;48(2):201\u20139. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00963.x (Epub 2007 Nov 28).","journal-title":"Headache."},{"issue":"4","key":"2801_CR33","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.4081\/ni.2014.5133","volume":"6","author":"L Hollanda","year":"2014","unstructured":"Hollanda L, Monteiro L, Melo A. Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. Neurol Int. 2014;6(4):5133. https:\/\/doi.org\/10.4081\/ni.2014.5133.","journal-title":"Neurol Int."},{"issue":"4","key":"2801_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","volume":"12","author":"G Sandrini","year":"2011","unstructured":"Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427\u201333. https:\/\/doi.org\/10.1007\/s10194-011-0339-z (Epub 2011 Apr 16).","journal-title":"J Headache Pain."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-021-02801-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T06:07:23Z","timestamp":1617170843000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-02801-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2801"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-02801-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}